Get started
Author

Katrin Pape

Immunoneuropsychiatry — novel perspectives on brain disorders
2019 · Katrin Pape, Ryad Tamouza, et al. · Nature Reviews Neurology · 459
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
2021 · Leoni Rolfes, Marc Pawlitzki, et al. · Neurology Neuroimmunology & Neuroinflammation · 116
PDF
β1-Integrin– and KV1.3 channel–dependent signaling stimulates glutamate release from Th17 cells
2019 · Katharina Birkner, Beatrice Wasser, et al. · Journal of Clinical Investigation · 57
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
2021 · Melanie Eschborn, Marc Pawlitzki, et al. · Neurology Neuroimmunology & Neuroinflammation · 54
PDF
Ocrelizumab initiation in patients with MS
2020 · Erik Ellwardt, Leoni Rolfes, et al. · Neurology Neuroimmunology & Neuroinflammation · 49
PDF
Impact of extended interval dosing of ocrelizumab on immunoglobulin levels in multiple sclerosis
2023 · Aaron Schuckmann, Falk Steffen, et al. · Med · 43
MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
2020 · Julia Loos, Steffen Pfeuffer, et al. · Journal of Neurology · 31
PDF
Implications of immunometabolism for smouldering MS pathology and therapy
2023 · Stefan Bittner, Katrin Pape, et al. · Nature Reviews Neurology · 18
Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score–matched study
2022 · Katrin Pape, Leoni Rolfes, et al. · Therapeutic Advances in Neurological Disorders · 17
Increased Disability Progression in rs10191329AA Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations
2024 · Maria Protopapa, Falk Steffen, et al. · Annals of Neurology · 14
PDF
Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
2020 · Katrin Pape, Falk Steffen, et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 10
Unveiling IRF4-steered regulation of context-dependent effector programs in CD4+ T cells under Th17- and Treg-skewing conditions
2025 · Anna Gabele, Maximilian Sprang, et al. · Cell Reports · 8
Recurrent late-onset neutropenia following treatment with different B cell-depleting strategies in multiple sclerosis
2024 · Maria Protopapa, Muriel Schraad, et al. · Med · 8
Role of CD5 signalling for pro-inflammatory Th17 response in multiple sclerosis
2025 · Katrin Pape, Nicholas Hanuscheck, et al. · Brain · 6
PDF
Cellular and humoral vaccination response under immunotherapies—German consensus on vaccination strategies in neurological autoimmune diseases
2025 · Muriel Schraad, Mathias Mäurer, et al. · Therapeutic Advances in Neurological Disorders · 5
Case Report: Balancing immune responses – multiple sclerosis disease exacerbation under BRAF/MEK treatment for malignant melanoma
2023 · Katrin Pape, Maria Protopapa, et al. · Frontiers in Oncology · 4
PDF
Bruton’s tyrosine kinase inhibitors rescue neuronal impairment caused by B cell–mediated lymphotoxin-α release
2025 · Josef Shin, Paul Götz, et al. · Science Translational Medicine · 3
Lower leukocytes pretreatment as a possible risk factor for therapy-induced leukopenia in interferon-beta-treated patients with multiple sclerosis
2024 · Maria Protopapa, Samantha Schmaul, et al. · Therapeutic Advances in Neurological Disorders · 3
Neues aus der Immuntherapie bei Multipler Sklerose
2018 · K. Pape, F. Zipp, et al. · Der Nervenarzt · 1
Unveiling IRF4-steered regulation of context-dependent effector programs in Th17 and Treg cells
2023 · Anna Gabele, Maximilian Sprang, et al. · bioRxiv (Cold Spring Harbor Laboratory)
PDF
Signatures of premature immunosenescence in patients with multiple sclerosis (P1-1.Virtual)
2022 · Melanie Eschborn, Marc Pawlitzki, et al. · Neurology
Meilenstein oder verpasste Chance?
2019 · Katrin Pape, Frauke Zipp · Der Nervenarzt
Works count: 34
Citation count: 906
H-index: 10
I10-index: 11
Year
Topic
Type